Acepodia (6976:TT), a biotech firm in the clinical stages, has released initial findings from its Phase 1 dose escalation trial of ACE1831. This therapy, a fusion of an anti-CD20 antibody with allogeneic gamma delta T cells, is aimed at treating non-Hodgkin's lymphoma (NHL).

Key Preliminary Results:

• Among five patients treated with the lowest dose of ACE1831, one achieved complete response (CR) and three experienced disease stabilization (SD). Notably, two of these patients had prior treatment with CD19 CAR-T.
• The clinical response persisted for three months following a single dose of ACE1831.
• The lowest dosage demonstrated good tolerance without serious adverse events or dose-limiting toxicities. Dose escalation continues.

ACE1831 marks Acepodia's debut cell therapy from its ACC platform, which employs bioorthogonal chemistry to link gamma delta 2 (γδ2) T cells with CD20-targeting antibodies. This method, rooted in Dr. Carolyn Bertozzi's Nobel Prize-winning work on click chemistry in living systems, offers a scalable, off-the-shelf alternative to CAR-T cell therapy, circumventing associated side effects like cytokine release syndrome and neurotoxicity. Preliminary data suggests ACE1831 activates both innate and adaptive immune responses, indicating a potentially broader immune reaction compared to standard CAR-T therapies.

Acepodia, sees this ongoing trial as a breakthrough, providing hope for patients with an innovative, patient-friendly approach.

The Phase 1 trial, involving up to 42 patients with relapsed/refractory NHL in the US and Taiwan, aims to assess ACE1831's safety, pharmacokinetics, and efficacy.

ACE1831, stemming from Acepodia's ACC platform, combines anti-CD20 antibody-conjugated gamma delta T cells to target CD20-expressing hematological cancers. Leveraging gamma delta T cells' high NK cell activating receptor expression to eliminate malignant blood cells, ACE1831 has shown promising cytotoxicity against cancer cells in preclinical studies. Currently, ACE1831 is undergoing Phase 1 evaluation in patients with non-Hodgkin's lymphoma.

 

Source: prnewswire.com

Report Abuse